Myriad Genetics to Acquire Precise Tumor, Precise Liquid and

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select

Related Keywords

Utah , United States , Glenn Farrell , Paulj Diaz , Matt Scalo , Intermountain Health System , Exchange Commission , Genetics Inc , Intermountain Precision Genomic , Tumor Test , Precise Liquid Test , Precise Tumor Test , Precise Tumor , Precise Liquid , Intermountain Healthcare , Solid Tumor , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports ,